













REVIEW



Navigating the Complexity of the Human Microbiome: Implications for Biomedical Science and Disease Treatment

Taiwo Temitope Ogunjobi^{1*}, Adaobi Mary-Ann Okafor², Nice Ifeanyi Ohuonu³ , Ngozi Maryann Nebolisa⁴, Ayomide Khadijat Abimbolu⁵ , Rufus Oluwagbemileke Ajayi⁶ , Akinwunmi Rapheal Afuape⁷, Mojisola Grace Ojajuni⁸ , Osarumwense Ona Ogunbor⁹ , Etido Udoh Elijah¹⁰ , Kayode Gbenga Akinwande¹¹ , Aiyebo Augustine Aigbagenode¹² , Tosin Sarah Olaniran¹³ , Adetola Adenike Adewoyin¹⁴ , Eniola Eunice Kolapo¹⁵  and Adnan Musa¹⁶ 

¹Department of Biochemistry, Ladoké Akintola University of Technology, Nigeria

²Department of Nutrition and Dietetics, University of Nigeria Nsukka, Nigeria

³Department of Microbiology, Michael Okpara University of Agriculture, Nigeria

⁴Department of Pharmacy, Nnamdi Azikiwe University, Nigeria

⁵Department of Natural Sciences, Middlesex University, UK

⁶Department of Public Health, University of Illinois at Springfield, USA

⁷Department of Biology, North Carolina Agriculture and Technical University, USA

⁸Department of Plant Biology and Biotechnology, Michael University of Medical Sciences, Nigeria

⁹Department of Microbiology, University of Benin, Nigeria

¹⁰Department of Microbiology, Nasarawa State University, Nigeria

¹¹Department of Pharmacology and Toxicology, University of Benin, Nigeria

¹²Department of Clinical Pharmacy and Pharmacy Practise, University of Benin, Nigeria

¹³Department of Food Science, University of Pretoria, South Africa

¹⁴Department of Biochemistry, The Polytechnic Ibadan, Nigeria

¹⁵Department of Pharmacy, University of Ibadan, Nigeria

¹⁶Department of Epidemiology, First Moscow State Medical University, Russia

Abstract: A multifaceted ecosystem of microorganisms that live in and on the human body is known as the human microbiome, and it is essential to both health and disease. The present review delves into the intricate nature of the microbiome and emphasizes its noteworthy consequences for both therapeutic interventions and biomedical science. By thoroughly analyzing existing research and techniques, such as next-generation sequencing and bioinformatics tools, we outline the makeup, variety, and dynamic interactions of the microbiome with the host. Important new information is provided by our analysis regarding the impact of the microbiome on immune regulation, metabolic pathways, and diseases like cancer, obesity, neurodegenerative diseases, and inflammatory bowel disease. We also address how the microbiome affects the pharmacokinetics and pharmacodynamics of medications, highlighting the significance of personalized medicine and drug development that considers the microbiome as well. Our findings have implications for the creation of new microbiome-based treatments, such as fecal microbiota transplantation, probiotics, prebiotics, and synbiotics, and they also highlight the potential of these treatments to treat dysbiosis-related illnesses. In order to improve treatment efficacy and patient outcomes, the review highlights the necessity of a paradigm shift in

*Corresponding author: Taiwo Temitope Ogunjobi, Department of Biochemistry, Ladoké Akintola University of Technology, Nigeria. Email: ttogunjobi@student.lau.tech.edu.ng

disease management and prevention strategies that incorporate microbiome modulation. As we move forward, we support improvements in the techniques used in microbiome research, a more thorough investigation of the interactions between the microbiome and the host, and the development of microbiome-based therapies. The directions for the future emphasize the value of personalized medicine techniques that use unique microbiome profiles to create individualized treatment plans. This thorough analysis provides a road map for maximizing the human microbiome’s potential in the treatment and prevention of disease by illuminating its complexity and wide-ranging implications for biomedical science.

Keywords: biomedical implications, disease treatment strategies, therapeutic microbial modulation, microbiome and immune regulation, microbiome-driven disease mechanism

1. Introduction

1.1. Overview of the human microbiome

The complex ecosystem of bacteria, viruses, fungi, and other microorganisms that live in and on the human body is known as the human microbiome. These microbial communities can be found in a variety of body habitats, including the mouth, respiratory tract, skin, and gut. Each of these habitats has a distinct microbial composition that reflects the physiological state of the host as well as the particular conditions of the local environment [1]. The development of advanced bioinformatics tools and high-throughput sequencing technologies has led to a significant advancement in our comprehension of the intricate role of the microbiome in human health and disease [2]. While “microbiota” refers to the organisms themselves, “microbiome” refers to the collective genome of all microorganisms in a given environment. When it comes to human health, the microbiome includes not only the genetic material of the microbial cells but also their interactions with the host and each other [3]. This complex web of interactions affects a variety of physiological processes, such as metabolism, immune function, and behavior, highlighting the significance of the microbiome as an essential part of the human organism. A wide variety of microorganisms make up the human microbiome [4] (Figure 1) [5]. The majority is made up of bacteria, with Firmicutes and Bacteroidetes dominating the gut microbiome and Actinobacteria and Proteobacteria being more prevalent on the skin. In addition to bacteria, the human body is home to a sizable number of viruses (the

virome), which can infect fungi (the mycobiome), bacteria (bacteriophages), and human cells. Every one of these elements has a distinct function in preserving homeostasis and enhancing the general well-being of the host [6].

The variety of the human microbiome is noteworthy in terms of genetic diversity in addition to species and strain diversity. Numerous factors, such as genetics, age, diet, lifestyle, and environmental exposures, all have an impact on this diversity. It is amazing that even identical twins can have different microbiomes, which emphasizes how important non-genetic factors are. The makeup of the microbiome is dynamic, altering in response to various factors such as pathological conditions, dietary changes, and developmental stages [7]. Understanding the role of the microbiome in health and disease requires taking individual variability in microbiome composition into account. This variability suggests that individual differences may occur in the effects of microbiome-modulating interventions, highlighting the need for tailored approaches in microbiome-related diagnostics and therapies. The microbiome of humans is a dynamic and intricate organism that is intricately linked to the host’s biology [8]. Its various components, which are impacted by environmental and genetic factors, are crucial for both preserving health and putting one at risk for illness. It takes an interdisciplinary approach to comprehend the complexities of the human microbiome, integrating knowledge from systems biology, genetics, immunology, and microbiology. The growing body of knowledge about the microbiome highlights its potential as a




Figure 1. Human microbiomes in different parts of the body

target for therapeutic intervention and a tool for personalized medicine, opening up new avenues for disease prevention and treatment in the field of biomedical science [9]. These bacteria can affect cancer progression and the outcome of other diseases.

The human microbiome is a wide range of microorganisms that live in the stomach, skin, oral cavity, respiratory system, and other parts of the body. These microorganisms include bacteria, viruses, fungi, and archaea. By aiding in digestion, producing vitamins, fending off infections, and regulating the immune system, these microbial communities are essential to preserving health. For example, bacterial phyla like Firmicutes and Bacteroidetes dominate the gut microbiota and are crucial for the fermentation of dietary fibers into short-chain fatty acids (SCFAs) that give colonocytes energy and have anti-inflammatory qualities. The *Staphylococcus* and *Propionibacterium* species that make up the majority of the skin microbiome are responsible for barrier function and pathogen defense [3]. Via processes like lysogeny and lysis, viruses found in the human microbiome, particularly bacteriophages, can affect the makeup and activity of bacterial communities. Despite being less common than bacteria, fungi are nevertheless an essential part of the microbiome, with species like *Malassezia* and *Candida* helping to preserve the health of the skin and mucous membranes. An imbalance in these microbial populations known as dysbiosis has been connected to several illnesses, including neurological problems, diabetes, obesity, and inflammatory bowel disease (IBD). Consequently, creating therapeutic approaches targeted at microbial balance restoration and health promotion requires a thorough understanding of the structure and function of the human microbiome [10].

1.1.1. Aim

This review aims to give a thorough overview of the human microbiome, emphasizing its importance and complexity in both health and disease. We want to clarify the functions of the various communities of microorganisms, such as bacteria, viruses, fungi, and archaea, that inhabit and are present in the human body. These microbes are involved in immune response, metabolic processes, and the maintenance of physiological homeostasis. This review emphasizes the significance of the microbiome in biomedical science by synthesizing recent research findings to provide insights into how microbial dysbiosis might cause a variety of disorders. It also investigates the implications of microbiome research for the prevention and treatment of disease. We discuss about how developments in sequencing and microbiome profiling technology have made it possible to comprehend host-microbe interactions and how they affect health outcomes on a deeper level. We demonstrated how manipulation of the microbiome via interventions like probiotics, prebiotics, fecal microbiota transplantation (FMT), and precision medicine techniques can potentially transform the treatment of conditions ranging from gastrointestinal disorders to metabolic and neurodegenerative diseases by examining case studies and clinical trials. Finally, this review aims to highlight the major obstacles and potential paths for microbiome research. We discuss the gaps in our knowledge of microbial ecosystems that exist now and the necessity of standardizing methods in research on microbiomes. This review aims to contribute to the current efforts to harness the microbiome for treating and enhancing health by offering a thorough examination of the complexity of the human microbiome and its biological implications.

The human gut is a diverse microbial ecosystem comprising viruses, fungi, archaea, and bacteria. These microbiomes affect cancer progression and inhibition in response to various treatments given to patients.

1.2. Historical perspective on microbiome research and its significance in biomedical science

The study of microbiomes has its roots in the first detection of microorganisms by Antonie van Leeuwenhoek with a crude microscope in the late 17th century. This discovery established the field of microbiology, but it was not until the late 19th and early 20th centuries that scientists started to recognize the abundance and variety of microbial life. The germ theory of disease was established by Louis Pasteur and Robert Koch, whose groundbreaking work connected particular microbes to infectious diseases and highlighted the role of microorganisms in human health [11]. Scientists were able to isolate and study individual microbial species via the development of culture-based techniques in the mid-20th century. These techniques were constrained, though, since they could only grow a tiny portion of the variety of microbes found in natural settings, such as the human body. The introduction of DNA sequencing tools in the late 20th and early 21st centuries transformed microbiome research. The Sanger sequencing method, established in the 1970s, was one of the first tools to provide extensive genetic research of bacteria, however, it was labor-intensive and expensive [12]. The real breakthrough was brought about by the development of next-generation sequencing (NGS) technologies, including whole metagenome sequencing (WMS) and 16S rRNA gene sequencing. These methods allowed for the high-throughput, low-cost analysis of complex microbial communities, exposing the wide range of diversity found in the human microbiome. The Human Microbiome Project, initiated in 2007, was a historic endeavor that aimed to characterize the microbial communities found in different parts of the human body and comprehend their functions in health and disease [13].

1.2.1. Implications and influences on medicine

1) Gut-brain axis and neurological health

The study of the gut-brain axis, a bidirectional communication network between the gut bacteria and the central nervous system, is one of the most important areas influenced by microbiome research. According to studies, gut bacteria can create neurotransmitters that affect behavior and brain function, like gamma-aminobutyric acid and serotonin. For example, studies have shown that changes in the composition of the gut microbiota can influence the synthesis of these neurotransmitters and inflammatory cytokines, which in turn can impair brain function [14].

The relationship between gut microbiota and mental health disorders, like anxiety and depression, is one prominent example. Clinical studies have shown that patients with these conditions frequently have dysbiosis, an imbalance in the composition of the gut microbiota. Probiotic treatments, which attempt to restore healthy gut microbiota, have shown promise in reducing the symptoms of anxiety and depression. For instance, a randomized controlled trial found that supplementing with strains of *Bifidobacterium* and *Lactobacillus* improved mood and cognitive function in patients with depression. These results suggest that microbiome modulation could be a novel therapeutic approach for mental health disorders [15].

2) Cancer therapy and oncology

Oncology has also benefited much from microbiome research, mostly in terms of knowing how gut bacteria might affect the course of cancer and how well a treatment works. The immune system's ability to identify and eliminate cancer cells can be influenced by the gut microbiome. Research has demonstrated that a particular

type of gut flora can improve the effectiveness of immune checkpoint inhibitors, a family of cancer immunotherapies

An investigation, for example, showed that *Bifidobacterium* in mice's gut microbiota enhanced the efficacy of anti-PD-L1 treatment, a popular immune checkpoint inhibitor. This discovery was published in science. Similar results have been seen in human trials, where immunotherapy was more effective in patients with a favorable gut microbiome makeup. To improve patient outcomes and the effectiveness of currently available cancer treatments, these findings have prompted researchers to investigate microbiome manipulation as an adjuvant therapy in oncology [16].

3) Metabolic disorders and obesity

Microbiome research has provided critical insights into the role of gut microbiota in metabolic health and disease. The gut microbiome is involved in nutrient absorption, energy metabolism, and the regulation of metabolic pathways. Dysbiosis has been linked to metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease. According to research, those who are obese frequently exhibit modifications to their gut microbiota composition, including an unbalanced ratio of Firmicutes to Bacteroidetes and a decreased diversity of microbial species. Improvements in metabolic parameters have been demonstrated when gut microbiota from lean donors is transplanted into obese recipients, indicating a potential causative role for gut microbiota in obesity. For instance, FMT from lean donors enhanced insulin sensitivity in individuals with metabolic syndrome who were obese, according to a clinical investigation. These results demonstrate the promise of microbiome-based treatments for managing metabolic diseases [17].

4) Infectious diseases and immune function

The human microbiome significantly influences the formation and function of the immune system. Studies have indicated that the gut microbiota can impact immune cell development, antimicrobial peptide synthesis, and the control of inflammatory responses. Numerous infectious illnesses and immune-related conditions have been linked to dysbiosis [18]. For example, changes in the gut microbiota have been associated with a higher risk of infections like *Clostridium difficile*, a serious bacterial infection that causes colitis. FMT has shown promise as a treatment for recurrent *C. difficile* infections, outperforming conventional antibiotic regimens in terms of success rates. FMT can compete with pathogenic bacteria and restore normal immune function by reestablishing a healthy gut microbiota [18].

2. Methodologies in Microbiome Research

2.1. Advances in sequencing technologies and bioinformatics for microbiome analysis

Advances in sequencing technologies and bioinformatics have significantly transformed the field of microbiome analysis, allowing for unprecedented insights into the composition, diversity, and functional roles of microbial communities within various environments, including the human body. This comprehensive overview will discuss major sequencing technologies and bioinformatics tools, addressing their limitations, potential sources of error, and strategies to mitigate these challenges [19].

2.1.1. NGS technologies

NGS technologies, such as Illumina sequencing, have revolutionized microbiome research by enabling high-throughput,

cost-effective sequencing of microbial DNA. Illumina sequencing, which utilizes massively parallel sequencing of short DNA fragments, is widely used for 16S rRNA gene sequencing to profile bacterial communities and for WMS to explore the functional potential of microbiomes. The abundance of data produced by NGS technologies (Table 1) [20] offers advantages as well as disadvantages [21]. In microbiome research, NGS technology represented a turning point (Figure 2) [20]. High-throughput, reasonably priced investigation of microbial genomes has been made possible by NGS platforms, such as Oxford Nanopore's long-read sequencing and Illumina's sequencing by synthesis.

However, Illumina sequencing has limitations, including short-read lengths that can complicate the assembly of complex microbial genomes and hinder the resolution of closely related species. Additionally, the issue of sample contamination is prevalent in microbiome research, where exogenous DNA can be introduced during sample collection, processing, or sequencing. To overcome these challenges, researchers employ rigorous contamination control measures, such as using negative controls, sterilizing equipment, and implementing stringent sample handling protocols.

2.1.2. Third-generation sequencing technologies

Third-generation sequencing technologies, including Pacific Biosciences and Oxford Nanopore Technologies, offer long-read sequencing capabilities that address some limitations of NGS. These technologies enable the sequencing of entire microbial genomes and the resolution of complex genomic regions, providing more accurate insights into microbial diversity and function [22]. Despite their advantages, third-generation sequencing technologies face challenges such as higher error rates compared to short-read technologies. Errors in nucleotide insertion, deletion, and substitution can occur, impacting the accuracy of the assembled genomes. To mitigate these issues, hybrid sequencing approaches that combine long-read and short-read data are often employed, leveraging the accuracy of short reads and the comprehensive coverage of long reads [23].

2.1.3. Metatranscriptomics and metaproteomics

Metatranscriptomics, the sequencing of RNA transcripts from microbial communities, provides insights into the active metabolic processes and gene expression profiles within the microbiome. Metaproteomics, which involves the large-scale study of proteins, further elucidates functional aspects by identifying and quantifying microbial proteins. Both approaches offer a dynamic view of microbial activity, complementing the static genetic information obtained from DNA sequencing [24].

However, metatranscriptomics and metaproteomics are technically challenging due to issues such as RNA instability, low RNA yields, and the complexity of protein extraction and identification. RNA degradation during sample collection and processing can lead to biased results. To address these challenges, researchers use RNA stabilization reagents, optimize extraction protocols, and employ advanced mass spectrometry techniques for protein analysis. Bioinformatics tools for metatranscriptomic and metaproteomic data integration are also being developed to enhance the interpretation of functional insights [24].

2.1.4. Bioinformatics tools and data integration

Bioinformatics plays a crucial role in microbiome analysis, encompassing data processing, quality control, taxonomic classification, functional annotation, and statistical analysis. Tools such as QIIME, Mothur, and DADA2 are widely used for 16S rRNA gene sequencing analysis, providing pipelines for sequence

Table 1. Different generations of NGS platforms

Platform	Use	Sequencing technology	Amplification type	Principle	Read length (bp)	Limitations
454 pyro sequencing	Short-read sequencing	Seq by synthesis	Emulsion PCR	Detection of pyrophosphate released during nucleotide incorporation.	400–1000	may have errors in the sequencing of deletions and insertions because the homopolymer length was not determined efficiently.
Ion Torrent	Short read	Seq by synthesis	Emulsion PCR	Ion semiconductor sequencing principle detecting H ⁺ ion generated during nucleotide incorporation.	200–400	Sequencing homopolymer sequences may result in a signal intensity drop.
Illumina	Short-read sequencing	Seq by synthesis	Bridge PCR	Solid-phase sequencing on immobilized surface leveraging clonal array formation using proprietary reversible terminator technology for rapid and accurate large-scale sequencing using single labeled dNTPs, which is added to the nucleic acid chain.	6–300	The sequencing may cause overcrowding or overlapping signals in the event of sample overloading, which might cause the error rate to spike by up to 1%.
DNA nanoball sequencing	Short-read sequencing	Seq by ligation	Amplification by Nanoball PCR	Splint oligo hybridization with post-PCR amplicon from libraries helps in the formation of circles. This circular ssDNA acts as the DNA template to generate a long string of DNA that self-assembles into a tight DNA nanoball. These are added to the aminosilane (positively charged)-coated flow cell to allow patterned binding of the DNA nanoballs. The fluorescently tagged bases are incorporated into the DNA strand, and the release of the fluorescent tag is captured using imaging techniques.	50–150	It takes longer to complete the workflow and requires multiple PCR cycles. This might be a restriction, along with the results of short-read sequencing.
Nanopore DNA sequencing	Long-read sequencing	Sequence detection through electrical impedance	Without PCR	The method relies on the linearization of DNA or RNA molecules and their capability to move through a biological pore called “nanopores”, which are eight nanometers wide. Electrophoretic mobility allows the passage of linear nucleic acid strand, which in turn is capable of generating a current signal.	Average 10,000–30,000	Up to 15% of errors can occur, particularly in sequences with modest complexity. Its read accuracy is worse than that of short-read sequencers.




Figure 2. Overview of NGS technologies: platforms and principles

quality filtering, chimera detection, and operational taxonomic unit clustering. For WMS, tools like MEGAHIT and MetaSPAdes are employed for metagenomic assembly, while functional annotation is facilitated by databases such as KEGG, COG, and Pfam [25].

A major challenge in bioinformatics is the accurate interpretation of large, complex datasets. Potential sources of error include sequencing artifacts, biases introduced during PCR amplification, and limitations in reference databases. To overcome these challenges, researchers employ multiple quality control steps, use reference-based and de novo assembly approaches, and apply statistical methods to account for biases. Integrating multi-omics data, including metagenomics, metatranscriptomics, and metaproteomics, enhances the robustness and comprehensiveness of microbiome studies, enabling a more holistic understanding of microbial ecosystems [25].

2.1.5. Sample contamination and control measures

Sample contamination remains a significant issue in microbiome research, as exogenous DNA can obscure true microbial signals and lead to erroneous conclusions. Common sources of contamination include laboratory reagents, environmental contaminants, and human handling. To minimize contamination, researchers implement strict protocols such as using DNA-free reagents, working in clean environments, and incorporating negative controls throughout the experimental workflow [26].

The utilization of NGS technologies has brought about a tremendous advancement in biomedical science and illness therapy by enabling us to navigate the intricate human microbiome in a revolutionary way. NGS technology enables unprecedentedly detailed microbiome characterization by enabling high-throughput, cost-effective investigation of microbial populations. This skill has made it possible to identify the wide range of microbial variety and complex microbial interactions that exist within the human body, clarifying their functions in both health and illness. In the field of biomedical science, NGS has made it easier to identify microbiome-related biomarkers for a range of illnesses, from neurological diseases to gastrointestinal problems, allowing for more accurate diagnosis and individualized treatment plans.

2.2. Challenges and considerations in microbiome study design, data analysis, and interpretation

2.2.1. Study design considerations

The reliability and validity of the research findings are greatly dependent on the design of microbiome studies. Sample contamination is a major design difficulty in research. Results can be considerably skewed by the introduction of contaminants at several stages, including sample collection, processing, and sequencing. Researchers need to take strict precautions to control contamination to address this. This entails adhering to strict decontamination procedures, utilizing sterile equipment, and implementing negative controls at every turn. To minimize the risk of contamination, for example, all processes should be carried out in clean settings and with DNA-free reagents and tools. Furthermore, using molecular methods to identify and measure possible contaminants, such as qPCR, can improve the accuracy of the findings [27].

Sample heterogeneity resulting from individual biological variability presents another problem. The microbiome's makeup can be influenced by a variety of factors, including genetics, nutrition, lifestyle, and environmental exposures. This can make actual connections with health or disease difficult to discern. Researchers should utilize closely matched control groups to account for confounding characteristics to mitigate this problem [28]. Reducing variability also requires standardizing sample collecting and processing techniques. To maintain consistency, it can be helpful to, for instance, collect samples at the same time of day, use the same kind of collection equipment, and process them in the same way. Large sample sizes and longitudinal studies can also assist take individual differences into account, enabling researchers to spot recurring trends and reach clearer findings [28].

2.2.2. Data analysis challenges

In microbiome research, data analysis poses several important issues. Ensuring proper sequencing depth and coverage is one of the main concerns. Low-abundance microbial species may escape

detection by insufficient sequencing depth, leaving incomplete microbiome profiles and possibly omitting important microbial actors implicated in health and illness. Researchers can use high-throughput sequencing platforms and optimize sequencing procedures to acquire higher depth to address this difficulty. Furthermore, to ensure more reliable comparisons, computational methods like rarefaction and normalization can assist in accounting for variations in sequencing depth between samples [29].

The intricacy of microbiome data, which is marked by noise and high dimensionality, is another significant obstacle. Meaningful patterns are hard to identify since microbiome databases usually contain a vast number of microbial taxa, many of which are present in low abundance. To manage this complexity, robust bioinformatics pipelines that incorporate statistical analysis, taxonomic assignment, and quality control are necessary. Finding pertinent patterns and relationships in the data can be facilitated by the application of advanced statistical approaches and machine-learning (ML) techniques. ML techniques, for instance, can be used to detect biomarkers, predict disease states, and classify samples according to the composition of their microbiomes [30].

2.2.3. Interpretation challenges

There are many difficulties in interpreting microbiome data, especially when it comes to linking the functional capabilities of the microorganisms to their makeup and recognizing how they affect the physiology of the host. The abundance and variety of microbial communities, which can differ greatly between people and over time, is one of the primary challenges. Because of this heterogeneity, it may be difficult to find reliable links between particular bacteria and health consequences. In order to overcome this difficulty, scientists can combine metagenomic, metatranscriptomic, and metabolomic data to learn more about the functional roles that various microbial species play. Metatranscriptomics can disclose the genes that are actively expressed, metabolomics may identify the metabolic products of microbial activity, and metagenomics can provide information on the genetic potential of the microbiome.

Another significant challenge is ensuring statistical power and reproducibility in microbiome studies. Small sample sizes and lack of reproducibility across studies can limit the reliability of findings, leading to conflicting results and hindering progress in the field. To enhance statistical power, researchers should design studies with adequate sample sizes and use appropriate statistical methods to control for multiple comparisons and confounding factors. Conducting replication studies and meta-analyses can also help validate findings across different populations and settings, providing more robust and generalizable conclusions [31]. Furthermore, the interpretation of microbiome data must consider the ecological context and interactions among microbial taxa. Microbial communities are dynamic and can be influenced by various factors, including diet, medication, and environmental exposures. Researchers should be cautious when making causal inferences based on observational data and consider conducting experimental studies to validate their findings. For example, animal models and *in vitro* experiments can help elucidate the mechanisms underlying observed associations and confirm the causal role of specific microbes in health and disease [32].

3. The Human Microbiome in Health and Disease

3.1. Role of the microbiome in maintaining homeostasis and immune system modulation

The human microbiome plays an important role in immune system regulation and physiological homeostasis maintenance

(Figure 3) [33]. It is an exciting topic of study with important implications for our understanding of health and illness. This complex web of microorganisms lives in many parts of the human body and engages in dynamic interactions with it to influence immune system development and performance, nutritional absorption, and metabolic activities [34]. From birth, bacteria colonize the stomach, growing into a diverse ecosystem that shapes and directs the human immune system. Through direct interactions with immune cells and metabolite formation, the microbiome influences both the development of immunological tolerance and the balance between pro- and anti-inflammatory responses. SCFAs, such as butyrate, acetate, and propionate, are important modulators of the immune response [35]. These SCFAs are produced when gut bacteria ferment food fibers. These metabolites support immunological homeostasis by modifying regulatory T-cell populations, affecting the synthesis of cytokines and chemokines, and strengthening the intestinal barrier [36]. Additionally, the body's protection against dangerous viruses depends on the microbiome. Colonization resistance arises when commensal bacteria prevent pathogens from colonizing and growing by means of mechanisms such as competitive exclusion and the production of antimicrobial compounds. This protective function highlights the importance of a healthy microbiome in preventing disease and maintaining well-being [37]. Dysbiosis, or disruptions in the microbiome, has been linked to a number of illnesses, such as type 2 diabetes, obesity, allergy diseases, and IBD. The complex relationship between the microbiome, immunological regulation, and disease is highlighted by the fact that such dysbiotic conditions can result in altered immune responses, increased intestinal barrier permeability, and systemic inflammation [38]. The human microbiome is necessary to maintain homeostasis and control the immune system. Understanding the complex interactions between the microbiota and the host opens the door to new treatment strategies that attempt to balance the microbiome, strengthen the immune system, and prevent or treat diseases linked to dysbiosis. This burgeoning field of inquiry holds promise for the development of microbiome-based therapies that promote health and combat disease [39].

Microbiome-derived TLR and NOD ligands and metabolites (e.g., SCFA and AhR ligands) act directly on enterocytes and intestinal immune cells, but can also reach remote tissues via the systemic circulation to modulate immunity. Peyer's patches are home to Th17 cells and Foxp3+ Treg cells, which support B-cell class switching and secretory (s)IgA production. They control the makeup of the homeostatic microbiota and aid in the compartmentalization of commensal bacteria. Differentiation of CD4+ Th17 cells is promoted by intestinal colonization by SFB and numerous other commensals. Furthermore, SFB colonization triggers signaling through the ILC3/IL-22/SAA1/2 axis, which causes ROR γ t+ Th17 cells to produce IL-17A. ILC3-derived IL-22 stimulates Th17 cells to produce IL-17A, which helps to confine particular microbiota members. Moreover, the deletion of MHCII produced by ILC3 stimulates CD4+ T cells specific to commensals, preventing an immunological response against innocuous colonists. Early-life microbial colonization suppresses the growth of iNKT cells, partly through sphingolipid synthesis, to avoid any pro-disease action in the lungs and intestinal lamina propria. The ability of colonization with *Bacteroides fragilis*, a well-known component of the mammalian gut microbiota, to balance the populations of Th1 and Th2 and to promote CD4+ T-cell development depends on its PSA. Via a TLR2-dependent process, PSA is picked up by lamina propria DCs and given to CD4+ T cells that are naïve. These cells have the ability to




Figure 3. Intestinal microbiota-immunity interplay in homeostasis

develop into regulatory T cells (iTreg) when activated TGF- β is present at the same time. These cells generate IL-10, which supports immunological homeostasis. On the other hand, IL-23 licensed via the same cascade encourages Th17 cells that are pro-inflammatory to proliferate. Selected mechanistically well-characterized microbiota-immune system interactions are depicted.

3.2. Dysbiosis and its association with diseases

Dysbiosis, a disturbance in the equilibrium of the microbial communities in the human microbiome, is becoming more widely acknowledged for its involvement in a range of illnesses, encompassing conditions beyond the gastrointestinal system, such as cancer and neurological diseases. Numerous causes, such as the use of antibiotics, food, stress, and environmental exposures, can result in this altered microbial state, which can cause changes in microbial composition and activity that are harmful to the health of the host [40].

3.2.1. Gastrointestinal disorders

Within the field of gastrointestinal disorders, dysbiosis has been shown to have a role in ailments like IBD, IBS, and Clostridium difficile infections (CDI). The methods by which dysbiosis affects these illnesses include modifications to the function of the mucosal barrier, deregulation of the immunological response, and adjustments to the microbial metabolite production process.

3.2.2. Neurological diseases

The notion of the “gut-brain axis” emphasizes how gut microbes might affect cerebral health in addition to the gut [41].

Changes in microbial composition may impact neuroinflammation and neurodegeneration through the synthesis of neuroactive chemicals, immune system modulation, and effects on the gut barrier. Dysbiosis has been related to neurodegenerative illnesses such as Parkinson’s and Alzheimer’s.

3.2.3. Cancer

The relationship between dysbiosis and cancer is complex; it includes changes in metabolites derived from microbes, immune system regulation, and the impact of the microbiome on the effectiveness of cancer treatments [42]. Certain gut bacteria have been linked to the toxicity and effectiveness of chemotherapeutic medicines through their metabolism, while other bacteria may influence the immune system’s capacity to identify and eliminate tumor cells.

3.2.4. Metabolic diseases

Dysbiosis has been linked to metabolic diseases like type 2 diabetes and obesity, where alterations in the microbiome can affect inflammation, insulin sensitivity, and energy metabolism [43].

3.2.5. Allergic diseases

The development of allergic illnesses is also influenced by the microbiome; early-life dysbiosis has been associated with a higher risk of developing asthma and atopic dermatitis, possibly through immune system modulation [9]. Dysbiosis plays an important role in the pathophysiology of many different diseases, including cancer, neurological ailments, and gastrointestinal issues.

4. Microbiome and Infectious Diseases

4.1. Interaction between the microbiome and pathogenic microorganisms

A key component of host-pathogen dynamics is the interaction between the human microbiome and pathogenic microbes, which affects susceptibility to infection and the course of disease. The etiology and development of infectious diseases are shaped by this intricate interplay, which takes place through a variety of processes such as direct microbial contacts, competition for resources, and modification of the host immune response [44]. Colonization resistance is one of the main ways that the microbiome affects pathogen colonization and infection. By competing with pathogens for vital nutrients and habitats, the indigenous microbial communities can inhibit pathogen adhesion to epithelial surfaces and so restrict pathogen development. Additionally, commensal bacteria have the ability to create antimicrobial compounds that stop the growth of pathogenic organisms, like bacteriocins and SCFAs [45].

Additionally, the host immune system is shaped by the microbiome, which has a significant impact on how the body reacts to pathogenic challenge. Commensal microorganisms support the development of both innate and adaptive immune responses as well as immune system maturation and function [33]. Microbial signals, for example, play a critical role in the preservation of the integrity of the mucosal barrier and in the activation of immune cells, such as dendritic cells and macrophages, that are able to identify and react to pathogenic threats. Furthermore, in the context of infection, the microbiome can affect the balance between immunological tolerance and activation by regulating the production of pro- and anti-inflammatory cytokines [46]. Pathogens and the microbiome do not always interact negatively; certain pathogens have developed ways to take advantage of the microbiome. Certain diseases have the ability to cause dysbiosis, or alterations in the makeup of the microbial population, which promotes their survival and growth. Some might use the metabolites that commensal bacteria make to become more virulent or to avoid being recognized by the immune system [47].

A major factor in both health and sickness is the complex relationship that exists between harmful bacteria and the human microbiome. Comprehending these dynamics can lead to the creation of new treatment approaches, such as modifying the microbiome to strengthen resistance to colonization, employing probiotics as competitive enemies against infections, and creating focused interventions to adjust the immune system [48].

4.2. The microbiome's role in resistance and susceptibility to infectious diseases

In order to control the host's resistance and susceptibility to infectious diseases, the human microbiome is essential. This intricate web of coexisting microbes influences host defenses through a variety of methods, but it also upholds a precarious equilibrium that, if upset, may make the host more susceptible to infection. Colonization resistance is one of the main ways the microbiome supports disease resistance [49]. Commensal microorganisms restrict the capacity of infections to establish themselves within the host by taking up ecological niches and eating available nutrients. The synthesis of antimicrobial compounds by some commensal bacteria, which can directly limit pathogen growth, supports this mechanism, which is essential in controlling the overgrowth of opportunistic pathogens [50].

Furthermore, the host immune system's growth and operation depend heavily on the microbiome. Commensal bacteria interact

with the host's mucosal surfaces to promote immune cell maturation and the generation of antibodies that provide protection. Through this contact, the immune system is primed to respond to pathogenic stimuli more quickly and efficiently. The management of inflammation is another area in which the microbiome plays a role in immune modulation [33]. A well-balanced microbial community facilitates a controlled and appropriate inflammatory response, which is essential for managing infections. Nevertheless, dysbiosis, or an imbalance in the microbiome, can compromise these defense mechanisms and make the host more vulnerable to viral illnesses [51]. Dysbiosis is a state of reduced microbial diversity and increased susceptibility to pathogenic microorganisms, which can be brought on by dietary modifications, antibiotic usage, and stress. This change has the potential to exacerbate an inflammatory response, impair immunological homeostasis, and weaken colonization resistance—all of which can aid in pathogen invasion and the advancement of disease [52].

The relevance of the microbiome in preserving health is highlighted by its impact on resistance and susceptibility to infectious diseases. It also emphasizes the possibility of using microbiome-targeted therapies to prevent or lessen infection [53]. Gaining insight into the complex interrelationships among pathogens, the immune system, and the microbiome can lead to innovative therapeutic approaches that strengthen host defenses while maintaining the integrity of the microbial population [33].

5. The Microbiome's Impact on Drug Metabolism and Efficacy

5.1. Microbiome influences the pharmacokinetics and pharmacodynamics of drugs

The human microbiota has a major impact on the pharmacokinetics and pharmacodynamics of medications, which in turn affects their overall therapeutic results, toxicity, and efficacy. The complicated ways in which the microbiome can impact drug metabolism (Figure 4) [54] (drug absorption, distribution, and metabolism) and excretion as well as the therapeutic benefits of the treatment are shown by this complex interplay between microbes and drugs [55]. One important field of research is medication metabolism mediated by the microbiome. Some commensal bacteria have special enzymatic pathways that allow medications to be biotransformed into compounds that are dangerous, inactive, or somewhere in between. For example, medicines that were once rendered inactive by hepatic glucuronidation may become active again due to bacterial β -glucuronidase activity in the gut, which could result in changes to the drug's toxicity or efficacy [56].

Additionally, a key factor in influencing a medicine's bioavailability is drug absorption, which is influenced by the microbiota. For instance, the integrity of the intestinal barrier may be modulated by gut bacteria, which may impact the oral bioavailability of specific medications [57]. Modifications in the makeup of microbes can impact tight junction protein expression, which can change intestinal permeability and, in turn, how well drugs are absorbed. Additionally, the distribution of drugs is influenced by the microbiome, especially when it comes to how it affects host metabolism and immunological responses. These changes can affect physiological states, the expression of drug transporters, and binding proteins. Microbial metabolites can also affect host metabolism and the pharmacological effects of pharmaceuticals by interacting with host receptors or enzymes involved in drug metabolism




Figure 4. Modes of drug metabolism

pathways [58]. The microbiome’s function in pharmacodynamics includes regulating how the body reacts to medications. The way that microbial metabolites interact with host receptors can either increase or decrease a drug’s therapeutic impact. For instance, some metabolites of microorganisms have the ability to activate host receptors related to pain, inflammation, and neurological processes, which can impact the effectiveness of analgesic and psychiatric drugs [58].

The understanding of how the microbiome affects pharmacokinetics and pharmacodynamics emphasizes the need for a more customized approach to medication therapy that takes the patient’s microbiome composition into account. This knowledge paves the door for developments in personalized medicine and pharmacotherapy by creating opportunities for improving medication regimens, creating microbiome-based therapies, and reducing adverse drug reactions [55].

The gut microbiota can perform metabolism of drugs by different modes of action: Drugs can be activated in the following ways: (A) by turning a prodrug into its active form; (B) by deactivating the drug, which reduces its therapeutic efficacy; (C) by turning the drug into a toxic metabolite, which causes an adverse drug reaction; (D) by reactivating the drug through enterohepatic recycling; (E) by directly binding the drug to microbial cells because of adhesive proteins on the microbial cell surface; (F) by competing with microbial metabolites for host enzymes; (G) by altering host gene expression and changing the expression of critical genes required for drug metabolism; (H) by immunomodulation or translocation of microbes, which promotes immune cell differentiation and develop autoimmunity.

5.2. Case studies on microbiome-mediated drug metabolism

The relationship between medication metabolism and the human microbiome provides strong support for the personalized medicine paradigm by highlighting the importance of taking into account the unique microbiome compositions of each patient when developing a pharmacological regimen. This concise review focuses on noteworthy case studies that shed light on how medication metabolism is affected by the microbiota, with implications for personalized medicine [56].

5.2.1. Irinotecan toxicity and bacterial β -glucuronidase

Irinotecan, a chemotherapeutic drug used to treat colorectal cancer, is detoxified by the liver by glucuronidation, which results in the formation of an inactive glucuronide conjugate (SN-38G), which is then eliminated into the intestines and bile. Nevertheless, β -glucuronidase activity allows gut bacteria like *Bacteroides* species and *Escherichia coli* to reactivate SN-38G to its deadly form, SN-38. Severe diarrhea is a typical side effect of irinotecan therapy that can result from this reactivation. Comprehending the individual differences in the composition of the gut microbiota may aid in predicting the vulnerability to irinotecan toxicity and customizing chemotherapy regimens accordingly [59].

5.2.2. Digoxin inactivation by *Eggerthella lenta*

Digoxin is a cardiac glycoside that is used to treat atrial fibrillation and heart failure. It was among the first medications found to be inactivated by *Eggerthella lenta*, a type of gut bacteria. Digoxin’s microbial metabolism has the potential to

greatly decrease both its bioavailability and therapeutic effectiveness. According to a study, arginine is one dietary component that might affect the metabolic activity of *E. lenta*. This suggests that patients who have high amounts of this bacterium may benefit more from digoxin therapy if their diet is altered [60].

5.2.3. Levodopa metabolism and the enteric microbiome

The main medication used to treat Parkinson’s disease, levodopa (L-dopa), is another instance of how the microbiota affects the effectiveness of a therapy. Before L-dopa enters the brain, certain strains of gut bacteria, such as *Enterococcus* and *Eggerthella* spp., can metabolize it, decreasing its efficiency and availability. Moreover, L-dopa’s microbial metabolism is unaffected by the concurrent administration of a peripheral decarboxylase inhibitor, which is meant to stop L-dopa from being converted to dopamine too soon in the peripheral [61]. For Parkinson’s patients with distinct microbial makeup, tailored therapies like probiotics or targeted antibiotics may enhance the efficacy of L-dopa therapy [62].

6. Therapeutic Exploitation of the Microbiome

6.1. Probiotics, prebiotics, and synbiotics: Mechanisms of action and clinical evidence

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit to the host. These beneficial bacteria and yeasts are commonly found in fermented foods and dietary supplements and are increasingly recognized for their role in maintaining and restoring gut health. Prebiotics are non-digestible food ingredients that selectively stimulate the growth and activity of beneficial microorganisms in the gut. Unlike probiotics, which are live organisms, prebiotics serve as food for these beneficial bacteria. Synbiotics are a combination of probiotics and prebiotics that work together synergistically to improve the gut microbiome and enhance the health benefits provided by each component. The probiotics in synbiotics help to populate the gut with beneficial bacteria, while the prebiotics serve as a food source to support their growth and activity.

A trio of functional foods and dietary supplements known as probiotics, prebiotics, and synbiotics are intended to positively impact the host by altering the makeup and activity of the gut microbiome. Their potential therapeutic benefits across a range of health issues are supported by their mechanisms of action (Figure 5) [63] and the growing body of clinical evidence [64]. Probiotics are live bacteria that give the host health benefits when given in sufficient doses. Their main mechanisms of action include strengthening the effectiveness of the gut barrier, generating antimicrobial compounds, competing with pathogenic bacteria for adhesion sites and nutrients, and modifying the immune system. Probiotics have been shown to be effective in treating and avoiding antibiotic-associated diarrhea, lowering the intensity and length of infectious diarrhea, and improving irritable bowel syndrome (IBS) symptoms [65]. Furthermore, several probiotic strains have demonstrated efficacy in treating ailments like allergic rhinitis and atopic dermatitis. Prebiotics are indigestible food ingredients that specifically promote the development and/or activity of healthy gut microbes. Dietary fibers and oligosaccharides, such as fructooligosaccharides and inulin, are mostly included in them. In order to produce SCFAs, which have systemic anti-inflammatory effects, increase gut barrier integrity, and control glucose and lipid metabolism, prebiotics function by providing substrates for fermentation by gut bacteria [66]. Their application in augmenting calcium absorption, promoting intestinal regularity, and possibly regulating the glycemic response is supported by clinical research. Synbiotics are a group of probiotics and prebiotics that work together to improve the activity and survival of good bacteria in the digestive system. Synbiotics work on the basis that prebiotics can feed probiotic strains specifically, increasing their ability to survive, colonize new areas, and function [67]. Clinical research on synbiotics is just getting started, but preliminary findings point to benefits in the treatment of IBS, the prevention of colorectal cancer, and the improvement of metabolic indicators in type 2 diabetes and obesity. The increasing number of studies on probiotics, prebiotics, and synbiotics shows how well they work together as complementary approaches to support gut health and other areas of health [68].




Figure 5. Mechanisms of probiotic action in the gut

This figure illustrates the mechanisms of probiotic action in the gut, including modulation of the immune response, enhancement of the gut barrier function, competitive exclusion of pathogens, and production of beneficial metabolites. In the first half of this figure, the gut microbiota modulation methods of probiotics and their effects on the enteric nervous system and IECs are demonstrated in (a). Probiotics can modify the gut microbiota by encouraging the development of mucins, promoting the adherence of competing microorganisms and/or excluding them, and producing antibacterial compounds such as poly-P, SCFAs, bacteriocins, AhR, and Nrf2 ligands. Probiotics also help to maintain tight junctions by stimulating the proliferation of IECs, preventing their apoptosis, and changing their cytokine profile via NF- κ B and MAPK signaling. Probiotics have been shown to modulate gut motility and reduce visceral sensitivity and pain through their interaction with the enteric nervous system. In the latter part (b), the processes by which probiotics modulate the immune system and inflammation are depicted. The primary immunologic change caused by probiotics is achieved by their contact with DCs, which promotes T-cell development and immune cell production of cytokines and sIgA by plasma cells. They can control the inflammatory response because probiotic contact alters the profiles of pro- and anti-inflammatory cytokines as well as the Th1 to Th2 ratio.

6.2. FMT

The goal of FMT (Figure 6) [69], a novel therapeutic approach, is to replenish the diversity and functionality of the gut microbiome by transferring stool from a healthy donor into the patient’s digestive system. This process has become more well-known, especially for treating recurrent CDI, for which it has demonstrated remarkable efficacy rates that are higher than those of conventional antibiotic therapies [70]. According to the principles of FMT, appropriate donors are chosen by a thorough screening process that looks for infectious agents and potentially harmful microbiota. The stool is then processed into a form suitable for transplantation, and the best administration route—a colonoscopy, nasogastric tube, or

encapsulated freeze-dried material—is selected. The standardization of the process, which involves figuring out the best formulation and dose, as well as resolving safety issues with the transmission of undesirable microorganisms or genetic material, are challenges in FMT. Since standards for patient permission, stool processing, and donor screening are always changing, ethical and regulatory issues also come into play [71].

The goal of FMT application and research in the future is to improve safety and efficacy through methodological refinement. In contrast to whole-stool transplantation, this involves the creation of synthetic or specified microbial consortia, which may provide more standardized and focused therapies. The field of microbiome science is moving toward individualized microbiota therapeutics based on a patient’s unique dysbiosis pattern [72] (Wilson et al., 2019). Important areas of continuing study include extending the use of FMT beyond CDI to other gastrointestinal disorders, such as IBD, and investigating its possible advantages in metabolic, neurological, and immunological conditions. FMT is a new and exciting way to treat disorders associated with dysbiosis by utilizing the potential of the human microbiome [73] (Hvas et al., 2019).

The two steps of fecal microbiota transplant. In Step 1, patients undergo bowel preparation with oral antibiotics followed by laxative. At least 24 h after the last dose of oral antibiotics, the patient will receive the donor fecal material via capsule, naso-enteral tubes, or upper or lower gastrointestinal endoscopy.

6.3. Emerging microbiome-based therapies and interventions in clinical trials

Utilizing the complex interaction between the human microbiome and health to create novel treatments for a range of disorders, emerging microbiome-based therapies and interventions represent a new frontier in medical science. The potential of these treatments for a variety of ailments, including metabolic diseases and gastrointestinal disorders, is currently being investigated in clinical trials. This emerging discipline, which offers individualized and targeted therapeutic alternatives, has the potential to completely transform how we manage and prevent disease [33]. FMT is a highly successful microbiome-based strategy that is primarily used to treat recurrent CDIs. Building on this achievement, ongoing clinical trials are examining the effectiveness of FMT and other microbiome modulators in the treatment of obesity, IBS, and IBD, with a particular emphasis on their capacity to modulate immune responses and restore microbial balance [74].

Developing specified microbial consortia as therapeutic agents is becoming more and more popular, even outside of FMT. These are intended to restore the proper makeup of the microbiome and are composed of certain blends of advantageous microorganisms chosen for their synergistic benefits. Trials are being conducted to assess the safety and effectiveness of these consortia in the treatment of dysbiosis-related illnesses. Using bacteriophages—viruses that infect and lyse particular bacterial strains—is another cutting-edge strategy [75].

Expanding upon this achievement, ongoing clinical trials are examining the effectiveness of FMT and additional microbiome modulators in ailments including IBD. Furthermore, modifying microbial metabolites offers a brand-new therapeutic approach. The development of therapies that modify these compounds—whether through dietary changes, prebiotics, or engineered bacteria that make or consume particular metabolites—is guided by our growing understanding of the roles played by particular metabolites in health and disease [74].




Figure 6. Fecal microbiota transplant

7. Technological and Ethical Considerations

7.1. The role of ML and artificial intelligence (AI) in microbiome research

The integration of ML and AI in microbiome research has ushered in a new era of understanding and application, significantly advancing our ability to interpret complex microbiome data and its implications for health and disease. These technologies are revolutionizing how we analyze microbial communities, predict disease states, and develop targeted therapies [76].

Recent studies illustrate the transformative impact of ML and AI in microbiome research. For example, ML algorithms have been employed to predict disease outcomes based on microbiome composition. Researchers have used supervised learning techniques to distinguish between healthy and diseased microbiome profiles, identifying microbial signatures associated with conditions such as IBD and colorectal cancer [77]. This predictive capability not only aids in early diagnosis but also informs personalized treatment strategies by targeting specific microbial imbalances. In addition to disease prediction, AI plays a crucial role in understanding the functional potential of microbial communities. AI-driven analyses can decipher complex interactions within the microbiome, highlighting how microbial metabolites influence host physiology and disease progression. For instance, AI models simulate how alterations in microbial composition affect the production of bioactive compounds, which may impact immune response modulation or metabolic pathways relevant to conditions like obesity and diabetes [78].

Moreover, ML and AI are accelerating drug discovery by identifying novel therapeutic agents from microbial sources. By integrating genomic data with AI algorithms, researchers can screen microbial genomes for bioactive compounds that target specific disease pathways. This approach has led to the discovery of antibiotics, immunomodulators, and even potential treatments for antibiotic-resistant infections, showcasing AI's potential to revolutionize drug development in microbiome-related fields [13].

7.2. Ethical, legal, and social implications of microbiome research and therapies

Significant ethical, legal, and social issues are raised by the expanding area of microbiome research and the creation of medicines based on microbiomes, which call for careful examination. With the growing comprehension of the human microbiome and its possible applications in customized medicine, these factors are essential in directing ethical investigations and treatment approaches. Given the extremely personal nature of microbiome data, privacy and confidentiality are among the main ethical problems [79]. Individuals may be uniquely identified by their microbiological signatures, which raises concerns regarding data security and the permission procedure. Furthermore, adhering to different regulatory frameworks and upholding privacy standards become increasingly difficult when microbiome data is shared between databases and nations [80]. Recent studies have underscored the necessity for robust anonymization techniques and stringent consent protocols to mitigate these privacy concerns.

The commercialization of microbiome-based medicines poses ethical and legal problems pertaining to treatment access and intellectual property rights. It might be difficult to ascertain who owns microbial strains utilized in therapeutics, especially those

that are generated from human individuals. Furthermore, a major social concern is providing fair access to these potentially expensive cures, emphasizing the necessity for regulations that strike a balance between innovation and accessibility [81]. Recent regulatory discussions have proposed models to ensure equitable distribution of microbiome-derived therapies, balancing patent protections with the need for public health access.

The public's dissemination of the results of microbiome research and its ramifications is a crucial factor to take into account. The significance of responsible reporting and public engagement initiatives to communicate the complexities and limitations of current information is highlighted by the fact that misinterpretation or oversimplification of outcomes can give rise to irrational expectations or unfounded worries [82]. Misinformation can lead to overhyped expectations about the therapeutic potential of microbiome interventions or unnecessary fears about their safety. Therefore, strategies for effective science communication and public education are paramount.

Ultimately, the use of microbiome-based therapies prompts inquiries concerning the modification of an individual's microbiome and its possible effects on identity and well-being. The idea of a "normal" microbiome makeup is still up for debate, and changing the microbiome may have unanticipated implications. For these reasons, extensive ethical review and ongoing safety monitoring are essential [83].

8. Future Perspectives and Challenges

8.1. Precision medicine through microbiome diagnostics and therapeutics

Precision medicine has tremendous future prospects as the human microbiome opens a frontier for the development of novel diagnostics and therapeutic techniques. In order to target the microbiome for diagnostic reasons, particular microbial signatures linked to both healthy and disease states must be identified. These signals may function as biomarkers for therapy response prediction, tracking the course of the disease, and early identification [84]. Dysbiosis patterns, for example, have been connected to diseases like IBD, obesity, and even mental health issues, indicating a wide diagnostic space that has not yet been well investigated. From the use of probiotics and prebiotics to modify microbial composition to more advanced methods like FMT to restore a healthy microbiota, the microbiome provides a wide range of therapeutic targets for intervention [85].

8.2. Challenges in large-scale and longitudinal microbiome research

The field nevertheless confronts several obstacles despite these promising opportunities. To determine causation and clarify the mechanisms behind microbiome-host interactions, large-scale, longitudinal research is necessary due to the complexity and heterogeneity of the microbiome between individuals [86]. These studies must address variations in the microbiome due to lifestyle, diet, environment, and genetic factors. Solutions include developing standardized protocols for sample collection and data analysis to minimize variability. Furthermore, leveraging advanced computational models and bioinformatics tools can help manage and interpret the vast datasets generated. Collaborative

efforts across institutions can also ensure comprehensive data collection and sharing, enhancing the reliability of findings.

8.3. Regulatory, ethical, and multidisciplinary challenges

Logistical, regulatory, and ethical factors also need to be taken into account, particularly when it comes to guaranteeing fair access and standardizing microbiome-based treatments. Ensuring equitable access to microbiome therapies requires the development of clear regulatory frameworks that balance innovation with patient safety and accessibility. Addressing these challenges involves creating guidelines for the ethical use of microbiome data, including privacy protections and informed consent procedures. Additionally, a multidisciplinary strategy incorporating knowledge from immunology, genetics, microbiology, and bioinformatics is needed to translate microbiome research into clinical practice. This emphasizes the difficulties in fully utilizing the microbiome's potential for diagnostics and treatments, along with the requirement for strong regulatory frameworks and public involvement [87].

8.4. Bridging the gap between microbiome research and clinical application

8.4.1. Translating research into clinical insights

Using the knowledge gained from microbiome research to improve human health will require bridging the gap between research and practical application. Despite its many difficulties, this project presents unprecedented chances to advance precision medicine. Converting the massive and intricate data produced by microbiome research into useful clinical insights is one of the main obstacles. The diversity of microbiomes among people, influenced by lifestyle, nutrition, environment, and genetics, complicates the identification of reliable, universal biomarkers for disease diagnosis or treatment [88]. Solutions include developing robust ML models to handle this complexity and identifying patterns within diverse datasets. Large-scale meta-analyses and data integration from multiple studies can enhance the generalizability of findings.

8.4.2. Developing and regulating microbiome-based therapies

The creation of treatments based on the microbiome, such as FMT, probiotics, and prebiotics, presents another major obstacle [89]. Rigorous clinical trials are required to ensure that these interventions are customized to each patient's needs and are thoroughly assessed for safety, efficacy, and long-term impacts. Furthermore, regulatory frameworks for these innovative treatments are still developing, necessitating precise rules to guarantee patient safety and effectiveness. Solutions involve establishing comprehensive regulatory guidelines and standardizing therapeutic protocols. Collaborative efforts between regulatory bodies, researchers, and clinicians can streamline the approval process and ensure consistent treatment standards.

8.4.3. Opportunities and collaborative efforts in clinical applications

The possibilities for using microbiome research in clinical settings are numerous, notwithstanding these obstacles. Individual microbiome profiles could inform personalized dietary plans and disease preventive tactics, significantly enhancing public health outcomes [90]. In addition, a variety of ailments, including metabolic and gastrointestinal conditions, may be treated completely differently thanks to microbiome-based diagnoses and treatments. Interdisciplinary collaboration is crucial to bridging the

knowledge gap between research and application, combining skills from genetics, medicine, microbiology, and bioinformatics [91]. Funding extensive microbiome projects and standardizing methods will be essential to improving our comprehension and use of microbiome science. Addressing these challenges will require cooperative, interdisciplinary efforts and ongoing innovation to fully realize the benefits of the microbiome for human health [25].

9. Conclusion

The trillions of bacteria that live in and on the human body make up the human microbiome, a complex ecosystem that is essential to both health and disease. The microbiome's enormous diversity and functioning have been revealed by recent developments in sequencing technologies and bioinformatics, underscoring its impact on the host's physiology, metabolism, and immune system. The microbiome influences nutrient absorption and energy balance by synthesizing vital vitamins, maintaining the intestinal barrier, and metabolizing food components. Numerous illnesses have been connected to dysbiosis, or an imbalance in the composition of the microbiome, including obesity, type 2 diabetes, IBD, cardiovascular disease, and even neurological issues. The microbiome affects these illnesses in a variety of ways, including immune response regulation, metabolic and genetic predisposition connections, and inflammatory modulation. Additionally, the pharmacokinetics and pharmacodynamics of medications are impacted by the microbiome, which impacts drug metabolism and efficacy. This has important ramifications for personalized medicine since it implies that knowing a person's microbiome composition could help with medication therapy optimization and adverse reaction reduction. As we currently understand it, the human microbiome plays a crucial role in both promoting health and reducing the risk of illness. This information presents new opportunities for customized medicine, therapeutic interventions, and microbiome-based diagnostics, all of which have promise for improving human health. However, there are obstacles to overcome in order to close the gap between research and clinical application, including interdisciplinary efforts, standardized procedures, and ethical considerations.

The human microbiome's amazing complexity and critical function in both health and sickness are highlighted by our present understanding of it. Within and on the human body, an intricate ecosystem of microorganisms, comprising bacteria, viruses, fungus, and archaea, interacts dynamically with the host. Studies have shed light on how the microbiome affects a number of physiological functions, including metabolism, immunological regulation, and pathogen defense. The microbial imbalance known as dysbiosis has been connected to a variety of illnesses, including cancer, obesity, neurological diseases, and IBD. This underscores the critical role that the microbiome plays in both maintaining health and causing disease.

The development of microbiome-based interventions (such as probiotics, prebiotics, and FMT) and the investigation of the microbiome's influence on drug toxicity and efficacy will be made possible by interdisciplinary research. It will also allow for the identification of particular microbial signatures linked to health states and disease progression. This all-encompassing method is expected to transform our comprehension of the microbiome and present novel approaches to illness prevention, diagnosis, and treatment, ultimately pushing the boundaries of customized medicine. To fully realize the promise of microbiome research to enhance human health and well-being, it is imperative to embrace its multidisciplinary nature.

Acknowledgement

We are sincerely grateful to Ladoke Akintola University of Technology, Ogbomosho, Nigeria, Department of Microbiology, University of Benin UNIBEN, Faculty of Life Sciences, Department of Public Health, University of Illinois at Springfield, USA, as well as Department of Food Science, University of Pretoria, Faculty of Natural and Agricultural Sciences South Africa for their moral support and encouragement towards this work.

Ethical Statement

This study does not contain any studies with human or animal subjects performed by any of the authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest to this work.

Data Availability Statement

The data that support this work are available upon reasonable request to the corresponding author.

Author Contribution Statement

Taiwo Temitope Ogunjobi: Conceptualization, Writing – original draft, Writing – review & editing. **Adaobi Mary-Ann Okafor:** Writing – review & editing. **Nice Ifeanyi Oluonu:** Investigation. **Ngozi Maryann Nebolisa:** Resources. **Ayomide Khadijat Abimbolu:** Methodology. **Rufus Oluwagbemileke Ajayi:** Validation. **Akinwunmi Rapheal Afuape:** Formal analysis. **Mojisola Grace Ojajuni:** Visualization. **Osarumwense Ona Ogunbor:** Supervision. **Etido Udoh Elijah:** Project administration. **Kayode Gbenga Akinwande:** Project administration. **Aiyebor Augustine Aigbagenode:** Methodology. **Tosin Sarah Olaniran:** Validation. **Adetola Adenike Adewoyin:** Formal analysis. **Eniola Eunice Kolapo:** Investigation. **Adnan Musa:** Resources.

References

- [1] Lai, S., Yan, Y., Pu, Y., Lin, S., Qiu, J. G., Jiang, B. H., . . . , & Zhao, X. M. (2023). Enterotypes of the human gut mycobiome. *Microbiome*, 11(1), 179. <https://doi.org/10.1186/s40168-023-01586-y>
- [2] Malla, M. A., Dubey, A., Kumar, A., Yadav, S., Hashem, A., & Abd_Allah, E. F. (2019). Exploring the human microbiome: The potential future role of next-generation sequencing in disease diagnosis and treatment. *Frontiers in Immunology*, 9, 2868. <https://doi.org/10.3389/fimmu.2018.02868>
- [3] El-Sayed, A., Aleya, L., & Kamel, M. (2021). Microbiota's role in health and diseases. *Environmental Science and Pollution Research*, 28(28), 36967–36983. <https://doi.org/10.1007/s11356-021-14593-z>
- [4] Ahn, J., & Hayes, R. B. (2021). Environmental influences on the human microbiome and implications for noncommunicable disease. *Annual Review of Public Health*, 42(1), 277–292. <https://doi.org/10.1146/annurev-publhealth-012420-105020>
- [5] Choudhry, H. (2021). The microbiome and its implications in cancer immunotherapy. *Molecules*, 26(1), 206. <https://doi.org/10.3390/molecules26010206>
- [6] Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., . . . , & Dinan, T. G. (2019). The microbiota-gut-brain axis. *Physiological Reviews*, 99(4), 1877–2013. <https://doi.org/10.1152/physrev.00018.2018>
- [7] Garud, N. R., & Pollard, K. S. (2020). Population genetics in the human microbiome. *Trends in Genetics*, 36(1), 53–67. <https://doi.org/10.1016/j.tig.2019.10.010>
- [8] Gilbert, J. A., Blaser, M. J., Caporaso, J. G., Jansson, J. K., Lynch, S. V., & Knight, R. (2018). Current understanding of the human microbiome. *Nature Medicine*, 24(4), 392–400. <https://doi.org/10.1038/nm.4517>
- [9] Tiffon, C. (2018). The impact of nutrition and environmental epigenetics on human health and disease. *International Journal of Molecular Sciences*, 19(11), 3425. <https://doi.org/10.3390/ijms19113425>
- [10] Hills, R. D., Pontefract, B. A., Mishcon, H. R., Black, C. A., Sutton, S. C., & Theberge, C. R. (2019). Gut microbiome: Profound implications for diet and disease. *Nutrients*, 11(7), 1613. <https://doi.org/10.3390/nu11071613>
- [11] Farré-Maduell, E., & Casals-Pascual, C. (2019). The origins of gut microbiome research in Europe: From Escherich to Nissle. *Human Microbiome Journal*, 14, 100065. <https://doi.org/10.1016/j.humic.2019.100065>
- [12] Johnson, J. S., Spakowicz, D. J., Hong, B. Y., Petersen, L. M., Demkowicz, P., Chen, L., . . . , & Weinstock, G. M. (2019). Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis. *Nature Communications*, 10(1), 5029. <https://doi.org/10.1038/s41467-019-13036-1>
- [13] The Integrative HMP (iHMP) Research Network Consortium. (2019). The integrative human microbiome project. *Nature*, 569(7758), 641–648. <https://doi.org/10.1038/s41586-019-1238-8>
- [14] Baj, A., Moro, E., Bistoletti, M., Orlandi, V., Crema, F., & Giaroni, C. (2019). Glutamatergic signaling along the microbiota-gut-brain axis. *International Journal of Molecular Sciences*, 20(6), 1482. <https://doi.org/10.3390/ijms20061482>
- [15] Ansari, S., & Yamaoka, Y. (2022). Animal models and *Helicobacter pylori* infection. *Journal of Clinical Medicine*, 11(11), 3141. <https://doi.org/10.3390/jcm11113141>
- [16] Mishra, S., Amatya, S. B., Salmi, S., Koivukangas, V., Karihtala, P., & Reunanen, J. (2022). Microbiota and extracellular vesicles in anti-PD-1/PD-L1 therapy. *Cancers*, 14(20), 5121. <https://doi.org/10.3390/cancers14205121>
- [17] Salem, F., Kindt, N., Marchesi, J. R., Netter, P., Lopez, A., Kokten, T., . . . , & Moulin, D. (2019). Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences. *United European Gastroenterology Journal*, 7(8), 1008–1032. <https://doi.org/10.1177/2050640619867555>
- [18] Bosco, N., & Noti, M. (2021). The aging gut microbiome and its impact on host immunity. *Genes & Immunity*, 22(5), 289–303. <https://doi.org/10.1038/s41435-021-00126-8>
- [19] Oulas, A., Pavloudi, C., Polymenakou, P., Pavlopoulos, G. A., Papanikolaou, N., Kotoulas, G., . . . , & Iliopoulos, L. (2015). Metagenomics: Tools and insights for analyzing next-generation sequencing data derived from biodiversity studies. *Bioinformatics and Biology Insights*, 9, BBI-S12462. <https://doi.org/10.4137/BBI.S12462>
- [20] Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., . . . , & Malonia, S. K. (2024). Correction: Satam et al. Next-Generation Sequencing Technology: Current Trends and Advancements. *Biology* 2023, 12, 997. *Biology*, 13(5), 286. <https://doi.org/10.3390/biology13050286>
- [21] Wensel, C. R., Pluznick, J. L., Salzberg, S. L., & Sears, C. L. (2022). Next-generation sequencing: Insights to advance clinical investigations of the microbiome. *The Journal of Clinical*

- Investigation*, 132(7), e154944. <https://doi.org/10.1172/JCI154944>
- [22] Karst, S. M., Ziels, R. M., Kirkegaard, R. H., Sørensen, E. A., McDonald, D., Zhu, Q., . . . , & Albertsen, M. (2021). High-accuracy long-read amplicon sequences using unique molecular identifiers with Nanopore or PacBio sequencing. *Nature Methods*, 18(2), 165–169. <https://doi.org/10.1038/s41592-020-01041-y>
- [23] Ashbury, F. D., Thompson, K., Williams, C., & Williams, K. (2021). Challenges adopting next-generation sequencing in community oncology practice. *Current Opinion in Oncology*, 33(5), 507–512. <https://doi.org/10.1097/CCO.0000000000000764>
- [24] Jagadeesan, B., Gerner-Smidt, P., Allard, M. W., Leuillet, S., Winkler, A., Xiao, Y., . . . , & Grant, K. (2019). The use of next generation sequencing for improving food safety: Translation into practice. *Food Microbiology*, 79, 96–115. <https://doi.org/10.1016/j.fm.2018.11.005>
- [25] Rajpoot, M., Sharma, A. K., Sharma, A., & Gupta, G. K. (2018). Understanding the microbiome: Emerging biomarkers for exploiting the microbiota for personalized medicine against cancer. *Seminars in Cancer Biology*, 52(1), 1–8. Academic Press. <https://doi.org/10.1016/j.semcancer.2018.02.003>
- [26] Zaura, E., Pappalardo, V. Y., Buijs, M. J., Volgenant, C. M. C., & Brandt, B. W. (2021). Optimizing the quality of clinical studies on oral microbiome: A practical guide for planning, performing, and reporting. *Periodontology*, 85(1), 210–236. <https://doi.org/10.1111/prd.12359>
- [27] Rawlinson, S., Ciric, L., & Cloutman-Green, E. (2019). How to carry out microbiological sampling of healthcare environment surfaces? A review of current evidence. *Journal of Hospital Infection*, 103(4), 363–374. <https://doi.org/10.1016/j.jhin.2019.07.015>
- [28] Van Rossum, T., Ferretti, P., Maistrenko, O. M., & Bork, P. (2020). Diversity within species: Interpreting strains in microbiomes. *Nature Reviews Microbiology*, 18(9), 491–506. <https://doi.org/10.1038/s41579-020-0368-1>
- [29] Kleine Bardenhorst, S., Berger, T., Klawonn, F., Vital, M., Karch, A., & Rübsamen, N. (2021). Data analysis strategies for microbiome studies in human populations—A systematic review of current practice. *mSystems*, 6(1), 10–1128. <https://doi.org/10.1128/mSystems.01154-20>
- [30] Ding, Y., Lei, X., Liao, B., & Wu, F. X. (2021). Machine learning approaches for predicting biomolecule–disease associations. *Briefings in Functional Genomics*, 20(4), 273–287. <https://doi.org/10.1093/bfpg/elab002>
- [31] Holmes, S. (2019). Successful strategies for human microbiome data generation, storage and analyses. *Journal of Biosciences*, 44(5), 111. <https://doi.org/10.1007/s12038-019-9934-y>
- [32] Cho, J. C. (2021). Omics-based microbiome analysis in microbial ecology: From sequences to information. *Journal of Microbiology*, 59(3), 229–232. <https://doi.org/10.1007/s12275-021-0698-3>
- [33] Zheng, D., Liwinski, T., & Elinav, E. (2020). Interaction between microbiota and immunity in health and disease. *Cell Research*, 30(6), 492–506. <https://doi.org/10.1038/s41422-020-0332-7>
- [34] Wang, J., Zhu, N., Su, X., Gao, Y., & Yang, R. (2023). Gut-microbiota-derived metabolites maintain gut and systemic immune homeostasis. *Cells*, 12(5), 793. <https://doi.org/10.3390/cells12050793>
- [35] Gao, J., Xu, K., Liu, H., Liu, G., Bai, M., Peng, C., . . . , & Yin, Y. (2018). Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. *Frontiers in Cellular and Infection Microbiology*, 8, 13. <https://doi.org/10.3389/fcimb.2018.00013>
- [36] Sun, M., Wu, W., Chen, L., Yang, W., Huang, X., Ma, C., . . . , & Cong, Y. (2018). Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. *Nature Communications*, 9(1), 3555. <https://doi.org/10.1038/s41467-018-05901-2>
- [37] Ducarmon, Q. R., Zwitterink, R. D., Hornung, B. V. H., Van Schaik, W., Young, V. B., & Kuijper, E. J. (2019). Gut microbiota and colonization resistance against bacterial enteric infection. *Microbiology and Molecular Biology Reviews*, 83(3), 1110–1128. <https://doi.org/10.1128/mmbr.00007-19>
- [38] Scheithauer, T. P. M., Rampanelli, E., Nieuwdorp, M., Vallance, B. A., Verchere, C. B., Van Raalte, D. H., & Herrema, H. (2020). Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. *Frontiers in Immunology*, 11, 571731. <https://doi.org/10.3389/fimmu.2020.571731>
- [39] Jiao, Y., Wu, L., Huntington, N. D., & Zhang, X. (2020). Crosstalk between gut microbiota and innate immunity and its implication in autoimmune diseases. *Frontiers in Immunology*, 11, 282. <https://doi.org/10.3389/fimmu.2020.00282>
- [40] Luca, M., Di Mauro, M., Di Mauro, M., & Luca, A. (2019). Gut microbiota in Alzheimer’s disease, depression, and type 2 diabetes mellitus: The role of oxidative stress. *Oxidative Medicine and Cellular Longevity*, 2019(1), 4730539. <https://doi.org/10.1155/2019/4730539>
- [41] Rutsch, A., Kantsjö, J. B., & Ronchi, F. (2020). The gut-brain axis: How microbiota and host inflammasome influence brain physiology and pathology. *Frontiers in Immunology*, 11, 604179. <https://doi.org/10.3389/fimmu.2020.604179>
- [42] Lotz, S. K., Blackhurst, B. M., Reagin, K. L., & Funk, K. E. (2021). Microbial infections are a risk factor for neurodegenerative diseases. *Frontiers in Cellular Neuroscience*, 15, 691136. <https://doi.org/10.3389/fncel.2021.691136>
- [43] Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018). The gut microbiota influences anticancer immunosurveillance and general health. *Nature Reviews Clinical Oncology*, 15(6), 382–396. <https://doi.org/10.1038/s41571-018-0006-2>
- [44] Manos, J. (2022). The human microbiome in disease and pathology. *Journal of Pathology, Microbiology and Immunology*, 130(12), 690–705. <https://doi.org/10.1111/apm.13225>
- [45] Jacobson, A., Lam, L., Rajendram, M., Tamburini, F., Honeycutt, J., Pham, T., . . . , & Monack, D. (2018). A gut commensal-produced metabolite mediates colonization resistance to *Salmonella* infection. *Cell Host & Microbe*, 24(2), 296–307. <https://doi.org/10.1016/j.chom.2018.07.002>
- [46] Gaffen, S. L., & Moutsopoulos, N. M. (2020). Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity. *Science Immunology*, 5(43), eaau4594. <https://doi.org/10.1126/sciimmunol.aau4594>
- [47] Kriss, M., Hazleton, K. Z., Nusbacher, N. M., Martin, C. G., & Lozupone, C. A. (2018). Low diversity gut microbiota dysbiosis: Drivers, functional implications and recovery. *Current Opinion in Microbiology*, 44, 34–40. <https://doi.org/10.1016/j.mib.2018.07.003>
- [48] Pascale, A., Marchesi, N., Marelli, C., Coppola, A., Luzi, L., Govoni, S., . . . , & Gazzaruso, C. (2018). Microbiota and metabolic diseases. *Endocrine*, 61, 357–371. <https://doi.org/10.1007/s12020-018-1605-5>
- [49] Dominguez-Bello, M. G., Godoy-Vitorino, F., Knight, R., & Blaser, M. J. (2019). Role of the microbiome in human

- development. *Gut*, 68(6), 1108–1114. <https://doi.org/10.1136/gutjnl-2018-317503>
- [50] Li, N., Ma, W. T., Pang, M., Fan, Q. L., & Hua, J. L. (2019). The commensal microbiota and viral infection: A comprehensive review. *Frontiers in Immunology*, 10, 1551. <https://doi.org/10.3389/fimmu.2019.01551>
- [51] Hassan, A., & Blanchard, N. (2022). Microbial (co) infections: Powerful immune influencers. *PLoS Pathogens*, 18(2), e1010212. <https://doi.org/10.1371/journal.ppat.1010212>
- [52] Lazar, V., Ditu, L. M., Pircalabioru, G. G., Gheorghe, I., Curutiu, C., Holban, A. M., . . . , & Chifiriuc, M. C. (2018). Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. *Frontiers in Immunology*, 9, 1830. <https://doi.org/10.3389/fimmu.2018.01830>
- [53] Libertucci, J., & Young, V. B. (2019). The role of the microbiota in infectious diseases. *Nature Microbiology*, 4(1), 35–45. <https://doi.org/10.1038/s41564-018-0278-4>
- [54] Jimonet, P., Druart, C., Blanquet-Diot, S., Boucinha, L., Kourula, S., Le Vacon, F., . . . , & Zimmermann, M. (2024). Gut microbiome integration in drug discovery and development of small molecules. *Drug Metabolism and Disposition*, 52(4), 274–287. <https://doi.org/10.1124/dmd.123.001605>
- [55] Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019). Separating host and microbiome contributions to drug pharmacokinetics and toxicity. *Science*, 363(6427), eaat9931. <https://doi.org/10.1126/science.aat9931>
- [56] Crouwel, F., Buitter, H. J. C., & de Boer, N. K. (2021). Gut microbiota-driven drug metabolism in inflammatory bowel disease. *Journal of Crohn's and Colitis*, 15(2), 307–315. <https://doi.org/10.1093/ecco-jcc/jjaa143>
- [57] van Berkel, S. S., & van Delft, F. L. (2018). Enzymatic strategies for (near) clinical development of antibody-drug conjugates. *Drug Discovery Today: Technologies*, 30, 3–10. <https://doi.org/10.1016/j.ddtec.2018.09.005>
- [58] Weersma, R. K., Zhermakova, A., & Fu, J. (2020). Interaction between drugs and the gut microbiome. *Gut*, 69(8), 1510–1519. <https://doi.org/10.1136/gutjnl-2019-320204>
- [59] Yue, B., Gao, R., Wang, Z., & Dou, W. (2021). Microbiota-host-irinotecan axis: A new insight toward irinotecan chemotherapy. *Frontiers in Cellular and Infection Microbiology*, 11, 710945. <https://doi.org/10.3389/fcimb.2021.710945>
- [60] Ruan, D., Fouad, A. M., Fan, Q. L., Huo, X. H., Kuang, Z. X., Wang, H., . . . , & Jiang, S. Q. (2020). Dietary L-arginine supplementation enhances growth performance, intestinal antioxidative capacity, immunity and modulates gut microbiota in yellow-feathered chickens. *Poultry Science*, 99(12), 6935–6945. <https://doi.org/10.1016/j.psj.2020.09.042>
- [61] van Kessel, S. P., Frye, A. K., El-Gendy, A. O., Castejon, M., Keshavarzian, A., van Dijk, G., & El Aidy, S. (2019). Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. *Nature Communications*, 10(1), 310. <https://doi.org/10.1038/s41467-019-08294-y>
- [62] Weis, S., Schwartz, A., Unger, M. M., Becker, A., Faßbender, K., Ratering, S., . . . , & Egert, M. (2019). Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota. *npj Parkinson's Disease*, 5(1), 28. <https://doi.org/10.1038/s41531-019-0100-x>
- [63] Simon, E., Călinoiu, L. F., Mitrea, L., & Vodnar, D. C. (2021). Probiotics, prebiotics, and synbiotics: Implications and beneficial effects against irritable bowel syndrome. *Nutrients*, 13(6), 2112. <https://doi.org/10.3390/nu13062112>
- [64] Kerry, R. G., Patra, J. K., Gouda, S., Park, Y., Shin, H. S., & Das, G. (2018). Benefaction of probiotics for human health: A review. *Journal of Food and Drug Analysis*, 26(3), 927–939. <https://doi.org/10.1016/j.jfda.2018.01.002>
- [65] Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019). Probiotics and prebiotics in intestinal health and disease: From biology to the clinic. *Nature Reviews Gastroenterology & Hepatology*, 16(10), 605–616. <https://doi.org/10.1038/s41575-019-0173-3>
- [66] Anania, C., Di Marino, V. P., Olivero, F., De Canditiis, D., Brindisi, G., Iannilli, F., . . . , & Duse, M. (2021). Treatment with a probiotic mixture containing *Bifidobacterium animalis* subsp. *Lactis* BB12 and *Enterococcus faecium* L3 for the prevention of allergic rhinitis symptoms in children: A randomized controlled trial. *Nutrients*, 13(4), 1315. <https://doi.org/10.3390/nu13041315>
- [67] Khanna, S., Bishnoi, M., Kondepudi, K. K., & Shukla, G. (2021). Synbiotic (*Lactiplantibacillus pentosus* GSSK2 and isomalto-oligosaccharides) supplementation modulates pathophysiology and gut dysbiosis in experimental metabolic syndrome. *Scientific Reports*, 11(1), 21397. <https://doi.org/10.1038/s41598-021-00601-2>
- [68] Kanazawa, A., Aida, M., Yoshida, Y., Kaga, H., Katahira, T., Suzuki, L., . . . , & Watada, H. (2021). Effects of synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes mellitus: A randomized controlled study. *Nutrients*, 13(2), 558. <https://doi.org/10.3390/nu13020558>
- [69] Bou Zerdan, M., Niforatos, S., Nasr, S., Nasr, D., Ombada, M., John, S., . . . , & Lim, S. H. (2022). Fecal microbiota transplant for hematologic and oncologic diseases: Principle and practice. *Cancers*, 14(3), 691. <https://doi.org/10.3390/cancers14030691>
- [70] Dembrovsky, F., Gede, N., Szakács, Z., Hegyi, P., Kiss, S., Farkas, N., . . . , & Péterfi, Z. (2021). Fecal microbiota transplantation may be the best option in treating multiple *Clostridioides difficile* infection: A network meta-analysis. *Infectious Diseases and Therapy*, 10, 201–211. <https://doi.org/10.1007/s40121-020-00356-9>
- [71] DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. A., Huntley, M. H., . . . , & Hohmann, E. L. (2019). Drug-resistant *E. coli* bacteremia transmitted by fecal microbiota transplant. *New England Journal of Medicine*, 381(21), 2043–2050. <https://doi.org/10.1056/NEJMoa1910437>
- [72] Wilson, B. C., Vatanen, T., Cutfield, W. S., & O'Sullivan, J. M. (2019). The super-donor phenomenon in fecal microbiota transplantation. *Frontiers in Cellular and Infection Microbiology*, 9, 2. <https://doi.org/10.3389/fcimb.2019.00002>
- [73] Hvas, C. L., Jørgensen, S. M. D., Jørgensen, S. P., Storgaard, M., Lemming, L., Hansen, M. M., . . . , & Dahlerup, J. F. (2019). Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent *Clostridium difficile* infection. *Gastroenterology*, 156(5), 1324–1332. <https://doi.org/10.1053/j.gastro.2018.12.019>
- [74] Caldeira, L. D. F., Borba, H. H., Tonin, F. S., Wiens, A., Fernandez-Llimos, F., & Pontarolo, R. (2020). Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis. *PLoS One*, 15(9), e0238910. <https://doi.org/10.1371/journal.pone.0238910>
- [75] Liu, C., Wang, Y. L., Yang, Y. Y., Zhang, N. P., Niu, C., Shen, X. Z., & Wu, J. (2021). Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. *The FASEB Journal*, 35(10), e21871. <https://doi.org/10.1096/fj.202100939R>

- [76] Sak, J., & Suchodolska, M. (2021). Artificial intelligence in nutrients science research: A review. *Nutrients*, 13(2), 322. <https://doi.org/10.3390/nu13020322>
- [77] Marcos-Zambrano, L. J., Karaduzovic-Hadziabdic, K., Loncar Turukalo, T., Przymus, P., Trajkovic, V., Aasmets, O., . . . , & Truu, J. (2021). Applications of machine learning in human microbiome studies: A review on feature selection, biomarker identification, disease prediction and treatment. *Frontiers in Microbiology*, 12, 634511. <https://doi.org/10.3389/fmicb.2021.634511>
- [78] Carrieri, A. P., Haiminen, N., Maudsley-Barton, S., Gardiner, L. J., Murphy, B., Mayes, A. E., . . . , & Pyzer-Knapp, E. O. (2021). Explainable AI reveals changes in skin microbiome composition linked to phenotypic differences. *Scientific Reports*, 11(1), 4565. <https://doi.org/10.1038/s41598-021-83922-6>
- [79] Ahmed, E., & Hens, K. (2022). Microbiome in precision psychiatry: An overview of the ethical challenges regarding microbiome big data and microbiome-based interventions. *AJOB Neuroscience*, 13(4), 270–286. <https://doi.org/10.1080/21507740.2021.1958096>
- [80] Woerner, A. E., Novroski, N. M. M., Wendt, F. R., Ambers, A., Wiley, R., Schmedes, S. E., & Budowle, B. (2019). Forensic human identification with targeted microbiome markers using nearest neighbor classification. *Forensic Science International: Genetics*, 38, 130–139. <https://doi.org/10.1016/j.fsigen.2018.10.003>
- [81] Volarevic, V., Markovic, B. S., Gazdic, M., Volarevic, A., Jovicic, N., Arsenijevic, N., . . . , & Stojkovic, M. (2018). Ethical and safety issues of stem cell-based therapy. *International Journal of Medical Sciences*, 15(1), 36–45. <https://doi.org/10.7150/ijms.21666>
- [82] Schelkle, B., & Galland, Q. (2020). Microbiome research: Open communication today, microbiome applications in the future. *Microorganisms*, 8(12), 1960. <https://doi.org/10.3390/microorganisms8121960>
- [83] Dixit, K., Chaudhari, D., Dhotre, D., Shouche, Y., & Saroj, S. (2021). Restoration of dysbiotic human gut microbiome for homeostasis. *Life Sciences*, 278, 119622. <https://doi.org/10.1016/j.lfs.2021.119622>
- [84] Schlager, R. (2020). Microbiome diagnostics. *Clinical Chemistry*, 66(1), 68–76. <https://doi.org/10.1373/clinchem.2019.303248>
- [85] Gagliardi, A., Totino, V., Cacciotti, F., Iebba, V., Neroni, B., Bonfiglio, G., . . . , & Schippa, S. (2018). Rebuilding the gut microbiota ecosystem. *International Journal of Environmental Research and Public Health*, 15(8), 1679. <https://doi.org/10.3390/ijerph15081679>
- [86] Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., . . . , & Danino, T. (2020). Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. *Science Translational Medicine*, 12(530), eaax0876. <https://doi.org/10.1126/scitranslmed.aax0876>
- [87] Cordaillat-Simmons, M., Rouanet, A., & Pot, B. (2020). Live biotherapeutic products: The importance of a defined regulatory framework. *Experimental & Molecular Medicine*, 52(9), 1397–1406. <https://doi.org/10.1038/s12276-020-0437-6>
- [88] Sharma, A., Das, P., Buschmann, M., & Gilbert, J. A. (2020). The future of microbiome-based therapeutics in clinical applications. *Clinical Pharmacology & Therapeutics*, 107(1), 123–128. <https://doi.org/10.1002/cpt.1677>
- [89] Chu, N. D., Crothers, J. W., Nguyen, L. T. T., Kearney, S. M., Smith, M. B., Kassam, Z., . . . , & Alm, E. J. (2021). Dynamic colonization of microbes and their functions after fecal microbiota transplantation for inflammatory bowel disease. *Mbio*, 12(4), 1110–1128. <https://doi.org/10.1128/mbio.00975-21>
- [90] Medina-Vera, I., Sanchez-Tapia, M., Noriega-López, L., Granados-Portillo, O., Guevara-Cruz, M., Flores-López, A., . . . , & Torres, N. (2019). A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes. *Diabetes & Metabolism*, 45(2), 122–131. <https://doi.org/10.1016/j.diabet.2018.09.004>
- [91] Wu, J., Wang, K., Wang, X., Pang, Y., & Jiang, C. (2021). The role of the gut microbiome and its metabolites in metabolic diseases. *Protein & Cell*, 12(5), 360–373. <https://doi.org/10.1007/s13238-020-00814-7>

How to Cite: Ogunjobi, T. T., Okafor, A. M. A., Oluonu, N. I., Nebolisa, N. M., Abimbolu, A. K., Ajayi, R. O., . . . , & Musa, A. (2024). Navigating the Complexity of the Human Microbiome: Implications for Biomedical Science and Disease Treatment. *Medinformatics*. <https://doi.org/10.47852/bonviewMEDIN42022988>

Abbreviations

SCFA	Short-chained fatty acid	TJ	Tight junction
AhR	Aryl hydrocarbon receptor	PP	Peyer's patch
Nrf2	Nuclear factor erythroid 2-related factor 2	TLR	Toll-like receptor
poly-P	Polyphosphate	LPS	Lipopolysaccharide
IEC	Intestinal epithelial cells	IL	Interleukin
MAPK	Mitogen-activated protein kinase	IFN- γ	Interferon- γ
NF- κ B	Nuclear transcription factor κ B	TGF- β	Transforming growth factor β
DC	Dendritic cell	TNF α	Tumor necrosis factor- α
sIgA	Secretory immunoglobulin A	BAFF	B-cell activating factor
Treg	Regulatory T cell	APRIL	A proliferation-inducing ligand
Th	Helper T cell	RA	Retinoic acid